Daily Technical Summary Reports on Generic Drugs Stocks -- Collegium Pharma, Momenta Pharma, Lipocine, and Diplomat Pharma
Aug 23, 2017, 06:25 ET
NEW YORK, August 23, 2017 /PRNewswire/ --
If you want a Stock Review on COLL, MNTA, LPCN, or DPLO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Pre-market today, DailyStockTracker.com has initiated coverage on Collegium Pharmaceutical Inc. (NASDAQ: COLL), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Lipocine Inc. (NASDAQ: LPCN), and Diplomat Pharmacy Inc. (NYSE: DPLO). Earlier this month, Chip Davis, CEO of the Association for Accessible Medicines, told CNBC on Power Lunch, "[Analysts are] pointing to some of the imbalances in the generic marketplace that haven't happened overnight, and that are continuing to evolve, but the reality is that the sustainable, robust competitive market is at risk now." He expects generic drugmakers will continue to feel pressure in the pharmaceutical market amid declining prices and nearly flat revenues. Register now and get full and free access to these DailyStockTracker.com research reports at:
On Tuesday, shares in Canton, Massachusetts headquartered Collegium Pharmaceutical Inc. recorded a trading volume of 348,161 shares. The stock ended at $9.34, declining 4.79% from the last trading session. The Company's shares have gained 1.74% over the previous three months. The stock is trading below its 50-day moving average by 20.07%. Furthermore, shares of Collegium Pharma, which develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases, have a Relative Strength Index (RSI) of 28.08.
On August 09th, 2017, Collegium Pharma reported its financial results for Q2 2017. For the quarter ended June 30th, 2017, net loss was $21.1 million; R&D expenses were $2.2 million; and SG&A expenses were $22.1 million. The Company had cash and cash equivalents of $111.2 million as of June 30th, 2017. Access our complete research report on COLL for free at:
Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock finished yesterday's session 3.27% higher at $15.80 with a total trading volume of 348,232 shares. The Company's shares have gained 7.48% over the previous three months and 4.98% on an YTD basis. The stock is trading above its 200-day moving average by 3.02%. Furthermore, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 41.42.
On August 02nd, 2017, Momenta Pharmaceuticals reported its financial results for Q2 ended June 30th, 2017. For Q2 2017, total revenues were $23.5 million; total GAAP operating expenses were $61.6 million; and net loss was $36.9 million. At June 30th, 2017, the Company had $456.8 million in cash, cash equivalents, and marketable securities. The complimentary research report on MNTA can be downloaded at:
On Tuesday, shares in Salt Lake City, Utah headquartered Lipocine Inc. saw a slight decline of 0.48%, ending the day at $4.17. The stock recorded a trading volume of 79,166 shares. The Company's shares have advanced 13.93% in the previous three months and 13.32% since the start of this year. The stock is trading 7.10% above its 200-day moving average. Moreover, shares of Lipocine have an RSI of 41.49.
On August 07th, 2017, Lipocine announced financial results for the three and six months ended June 30th, 2017. For Q2 2017, net loss was $6.1 million; R&D expenses were $4.1 million; and G&A expenses were $2.0 million. For the six months ended June 30th, 2017, net loss of $11.0 million; R&D expenses were $7.2 million; and G&A expenses were $3.9 million. Register for free on DailyStockTracker.com and get access to the latest report on LPCN at:
Flint, Michigan headquartered Diplomat Pharmacy Inc.'s shares ended the day 0.67% higher at $16.54 with a total trading volume of 292,986 shares. The stock has gained 6.85% in the last month and 31.27% on an YTD basis. The Company's shares are trading 2.81% above their 50-day moving average and 8.80% above their 200-day moving average. Additionally, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 52.93.
On August 17th, 2017, Diplomat Pharmacy announced that it is dispensing newly approved MAVYRET™ (glecaprevir and pibrentasvir) oral tablets for chronic hepatitis C virus infection. MAVYRET is indicated for patients with all major genotypes (1-6) of chronic hepatitis C virus infection without cirrhosis (liver disease) or with compensated cirrhosis. It is the first, eight-week treatment duration approved for all genotypes in adult patients without cirrhosis who have not been previously treated. Download your free research report on DPLO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article